
    
      In Part A, patient participation is expected to last up to 63 days, including a 28-day
      screening period(consisting of a 7-day diary run-in to build baseline itch NRS) and a 36-day
      on study period (consisting of 56 total doses from Day 1 to Day 29, and a 7 day follow-up/EOS
      visit at Day 36).

      In Part B, patient participation is expected to last up to 85 days, including a 28-day
      screening period (consisting of a 7-day diary run-in to build baseline itch NRS) and a 57-day
      on study treatment period.
    
  